Randomized Trialhigh evidence
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
Lancet (London, England)·May 30, 2026·PMID 41865758
Why it mattersGLP-1 receptor agonists have generated interest for potential neuroprotection, but these large, rigorous trials provide definitive evidence that oral semaglutide does not benefit early Alzheimer's disease. This informs prescribing decisions and redirects research focus.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled